Matching the dose to the disease: Successful treatment of recalcitrant pyoderma gangrenosum using high‐dose secukinumab

Coe, James; Kudva, Shobha; Shams, Kave

doi:10.1111/dth.15669

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-17 Inhibitors IL-17 inhibitors are a group of novel biological drugs that inhibit the activity of IL-17. The available literature describes the effects of treatment with three representatives of this group (secukinumab, ixekizumab, and brodalumab) [149][150][151]. The reports regarding the use of this group of biologic drugs and PG is ambiguous.…”

Section: Il-1 Antagonistsmentioning

confidence: 99%

See 1 more Smart Citation

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

Łyko,

Ryguła,

Kowalski

et al. 2024

IJMS

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an uncommon inflammatory dermatological disorder characterized by painful ulcers that quickly spread peripherally. The pathophysiology of PG is not fully understood; however, it is most commonly considered a disease in the spectrum of neutrophilic dermatoses. The treatment of PG remains challenging due to the lack of generally accepted therapeutic guidelines. Existing therapeutic methods focus on limiting inflammation through the use of immunosuppressive and immunomodulatory therapies. Recently, several reports have indicated the successful use of biologic drugs and small molecules administered for coexisting diseases, resulting in ulcer healing. In this review, we summarize the discoveries regarding the pathophysiology of PG and present treatment options to raise awareness and improve the management of this rare entity.

show abstract

Section: Il-1 Antagonistsmentioning

confidence: 99%

“…The reports regarding the use of this group of biologic drugs and PG is ambiguous. Secukinumab, a first-in-class fully human monoclonal antibody against interleukin-17A, was successfully used in several case reports [149,152,153]. However, there are existing data on the paradoxical reactions to it.…”

Section: Il-1 Antagonistsmentioning

confidence: 99%

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

Łyko,

Ryguła,

Kowalski

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…In another report, secukinumab was used to successfully treat a patient with recalcitrant PG, and corresponded with a decrease in DLQI score from 24/30 to 3/30. Importantly, in this patient minimal improvement was seen at a four-weekly dosing, and significant improvement was only seen after dosing was increased to twice weekly [ 49 ]. Several reports also detailed success with secukinumab in treating various PG phenotypes, including PASS syndrome [ 50 ] and PsAPSASH syndrome [ 51 ].…”

Section: Pyoderma Gangrenosummentioning

confidence: 99%

Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review

Mital

Gray

Minta

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

With advances in drug development and our understanding of the pathophysiology of skin disease, biologic medications have emerged as powerful management tools for dermatologists. While biologics have most often been used in the management of psoriasis, they are being used off-label for the management of a variety of other immune-mediated skin diseases with overlapping molecular targets. This narrative review focuses on the novel and off-label use of biologic medications for the management of hidradenitis suppurativa (HS), pyoderma gangrenosum (PG), lichen planus (LP), and seborrheic dermatitis (SD). Review of the literature revealed that IL-17, IL-23, and tumor necrosis factor (TNF) inhibitors were being used across a variety of immune-mediated skin pathologies with variable efficacy, among other targeted biologics. While biologics were generally safe in the treatment of primary immune-mediated skin disorders, paradoxical disease eruptions were noted with biologic use and were theorized to occur owing to immune dysregulation and cytokine imbalance. While numerous case reports show promise for the use of biologics in immune-mediated skin pathologies, the variable efficacy and safety reported warrants more thorough investigations of the role of these targeted medications in comprehensive disease management.

show abstract

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Matching the dose to the disease: Successful treatment of recalcitrant pyoderma gangrenosum using high‐dose secukinumab

Cited by 4 publications

References 9 publications

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review

Antineoplastics

Contact Info

Product

Resources

About